Patents
Literature
36 results about "Intestinal bacterium" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method for producing 1, 3-propylene glycol through ferment in high cell density by using bacteria in intestinal tract
A method of preparing 1, 3- propylene glycol by high cell density intestinal uses the method of fermentation. Its process: seed culturing the intestinal bacterium is activated and then inoculated in the nutrient solution with no bacterium seed; the raises process of fermentation nutrient solution: when this solution is disinfected and cool, we inoculate the seed solution with the volume rate 3-15% into a tank of fermentation solution; the fast grow period of separated fermentation solution: the density of carbon retains 0.1-30g / L; high cell density fermentation period: the density of the bacterium seed reaches OD6502.0-5.0; it adapts the way of limited accommodate of alimentation and air; when the product has been synthesized, we add nitrogen, phosphate, inorganic ion, trace element,VB12 or their mixture of one or several components, and simultaneously add flowing glycerin; when there is acid, the fermentation process finishes.
Owner:SOUTHEAST UNIV
Microbial fermentation feed for litopenaeus vannamei
InactiveCN103583880AThe fermentation process is simpleReduce manufacturing costAnimal feeding stuffMicroorganismAgricultural science
The invention discloses a microbial fermentation feed for litopenaeus vannamei. The microbial fermentation feed is prepared by the following specific steps: after fully mixing photosynthetic bacteria and bacillus, adding brown sugar and uniformly mixing to obtain a mixture A; uniformly spraying the mixture A on a commercially available feed for litopenaeus vannamei to obtain a mixture B; filling the mixture B in a sealed container, and sealing at a normal temperature for fermenting, wherein the fermentation is completed when the temperature of the center of the sealed container rises to 45 DEG C; and taking out a fermented mixture B, air-drying and bagging to obtain the microbial fermentation feed for the litopenaeus vannamei. The microbial fermentation feed for the litopenaeus vannamei, provided by the invention, is suitable for a later charging amount rapid-increasing stage during aquaculture of the litopenaeus vannamei, and is a health care functional feed product which has the functions of increasing the feed utilization rate and the digestibility, protecting the liver of the litopenaeus vannamei and promoting the intestinal bacterium equilibrium.
Owner:SHANGHAI FANYONG BIOTECH
Mulberry pomace chicken feed and preparation method thereof
InactiveCN105053602APromote growth and developmentGrowth inhibitionFood processingAnimal feeding stuffWeight gainingBiotechnology
The present invention provides a mulberry pomace chicken feed and a preparation method thereof. The mulberry pomace chicken feed comprises the following raw materials in weight percentage: 20-30% of mulberry pomace powder, 10-15% of corn flour, 10-12% of rice bran, 4-8% of molasses, 10-15% of soybean meal powder, 10-15% of wheat bran, 5-8% of mulberry leaf powder, 8-12% of mulberry branches, 1-5% of atractylodes lancea, 2-4% of mirabilite, 5-8% of dried orange peels, 2-3% of ammonium sulfate, 0.2-0.5% of monopotassium phosphate and 0.05-0.08% of magnesium sulfate. The provided chicken feed is rich in raw material variety and adequate in nutrition, and is free of any chemical medicines. The feed after fermentation is fragrant in smell, is high in protein content, and is good in palatability. The food intake of chicken flocks is increased, the growth and development of chicken is fast, and the daily weight gain of chicken is increased significantly. The chicken feed can improve the production performance of chicken, significantly improve the intestinal environment of chicken, promote intestinal bacterium growth and reproduction, and inhibit the growth of harmful bacteria.
Owner:AGRI PROD PROCESSING INST GUANGXI ACADEMY OF AGRI SCI
Microbial fermentation feed for litopenaeus vannamei
InactiveCN103583880BThe fermentation process is simpleReduce manufacturing costAnimal feeding stuffBacteroidesAgricultural science
The invention discloses a microbial fermentation feed for litopenaeus vannamei. The microbial fermentation feed is prepared by the following specific steps: after fully mixing photosynthetic bacteria and bacillus, adding brown sugar and uniformly mixing to obtain a mixture A; uniformly spraying the mixture A on a commercially available feed for litopenaeus vannamei to obtain a mixture B; filling the mixture B in a sealed container, and sealing at a normal temperature for fermenting, wherein the fermentation is completed when the temperature of the center of the sealed container rises to 45 DEG C; and taking out a fermented mixture B, air-drying and bagging to obtain the microbial fermentation feed for the litopenaeus vannamei. The microbial fermentation feed for the litopenaeus vannamei, provided by the invention, is suitable for a later charging amount rapid-increasing stage during aquaculture of the litopenaeus vannamei, and is a health care functional feed product which has the functions of increasing the feed utilization rate and the digestibility, protecting the liver of the litopenaeus vannamei and promoting the intestinal bacterium equilibrium.
Owner:SHANGHAI FANYONG BIOTECH
Primer compound for identifying intestinal microecological state and application thereof
ActiveCN109576386AEfficient and convenient identificationHigh detection specificityMicrobiological testing/measurementMicroorganism based processesBacteroidesClostridium symbiosum
The invention provides a primer compound for identifying intestinal microecological state and an application thereof. The primer compound is a specific primer designed for intestinal bacterium 16S rRNA; the specific primer includes random basic groups; the quantity of random basic groups is 3-5; the intestinal bacterium includes any one of or combination of at least two of symbiotic clostridia, bifidobacterium adolescentis, fusobacterium nucleatum, peptostreptococcus anaerobius or klebsiella. A kit researched and developed on the basis of the primer compound provided by the invention has a specificity for detecting intestinal microecological imbalance reaching up to 92.5% and a sensitivity reaching up to 80.43%.
Owner:SUZHOU PRECISION BIOTECH CO LTD
Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion
InactiveCN101553480AExcellent anti-helicobacter pylori effectInhibition of secretionAntibacterial agentsOrganic active ingredientsAntimicrobial actionAntibacterial agent
The invention provides a compound which is stable in an acid, has an antibacterial effect against a bacterium Helicobacter pylori, can exert a satisfactory level of an antibacterial effect when used singly, does not affect an enteric bacterium, has an antibacterial effect against a bacterium resistant to an antibacterial agent, and has an inhibitory effect on gastric acid secretion; and a pharmaceutical composition comprising the compound. Specifically disclosed are: a compound represented by the general formula (I) or a salt thereof; and a pharmaceutical composition comprising the compound or the salt thereof. (I) wherein R represents a linear alkyl group having 4 to 8 carbon atoms, preferably 5 to 7 carbon atoms.
Owner:LINK GENOMICS
Application of mushroom dietary fiber extracts for preparing pharmaceutical preparation for treating and/or preventing diseases associated with intestinal bacterium community disorder
The invention relates to the application of mushroom dietary fiber extracts in the field of pharmaceutics, in particular to the application of the mushroom dietary fiber extracts for preparing a pharmaceutical preparation for treating and / or preventing diseases associated with intestinal bacterium community disorder and a preparation method thereof. The extracts are significantly beneficial to restoration of a dominant bacteria structure in intestines, diversity of bacteria is facilitated, significant treating and / or preventing effects on the diseases associated with an intestinal bacterium community structure are shown, for example, expression of inflammatory factors can be effectively inhibited to effectively relieve the deterioration of inflammation, each item of physiological and pathological indexes related to immune is improved, the extracts can be applied to the fields of medicine, health products and the like, and the extracts have significant economic and social value.
Owner:GUANGDONG INST OF MICROBIOLOGY GUANGDONG DETECTION CENT OF MICROBIOLOGY +1
Laminarinase OUC-L1 and encoding gene and application thereof
ActiveCN111334488AEffective for hydrolysisGood coldnessHydrolasesFermentationNucleotideOligosaccharide
The invention discloses laminarinase OUC-L1. The amino acid sequence of the laminarinase OUC-L1 is shown as SEQ ID NO:1, the gene of the laminarinase OUC-L1 is encoded, and the nucleotide sequence ofthe laminarinase OUC-L1 is shown as SEQ ID NO. 2. The laminarinase OUC-L1 is explored from a human intestinal bacterium A. muciniphila genome, belongs to a glycoside hydrolase GH16 family, and can effectively hydrolyze laminarin, and the main product of the laminarinase OUC-L1 is three parts of oligosaccharides, has high specific enzyme activity and good biological catalysis efficiency, and has the highest reaction activity at the temperature of 35 DEG C. In addition, the laminarinase OUC-L1 also has good cold adaptability. The invention further discloses an enzyme preparation containing the laminarinase OUC-L1. The enzyme preparation still has considerable catalytic activity at low temperature and has good industrial application potential.
Owner:OCEAN UNIV OF CHINA
Traditional Chinese medicine for treating and/or preventing gastrointestinal dysfunction caused by critical diseases
InactiveCN103656450APrevent gastrointestinal dysfunctionGood treatment effectHeavy metal active ingredientsDigestive systemDiseaseIntestinal walls
The invention aims to provide a traditional Chinese medicine for treating and / or preventing gastrointestinal dysfunction caused by critical diseases. The traditional Chinese medicine is prepared from the following raw materials: radix codonopsis, fried largehead atractylodes rhizome, poria cocos, honey-fried licorice root, Chinese yam, white hyacinth bean, coix seed, villous amomum fruit, balloonflower root, pomegranate rind, myrobalan, and red halloysite. The traditional Chinese medicine is prepared according to the theories of tonifying qi, invigorating the spleen, upbearing the clear, and downbearing the turbid, has an integral conditioning effect by simultaneously eliminating and supplementing; can promote the peristalsis and propulsion of gastrointestinal smooth muscle, improves the blood circulation of the intestinal walls, reduces the capillary permeability of the gastrointestinal tracts, relieves the tissue edema, promotes the discharge of dead tissues, inhibits the intestinal bacterium translocation and toxin absorption in the intestines, eliminates the free radicals, and antagonizes the system inflammation reaction. The traditional Chinese medicine for treating gastrointestinal dysfunction caused by critical diseases has a good effect, can control the incidence rate of gastrointestinal dysfunction below 19.05%, does not have any side or toxic effect during the clinical process, and is reliable and safe.
Owner:LIUZHOU HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Method for examination of carcinogenic risk
ActiveUS20150376716A1Reduce cancer riskImprove the situationCompound screeningApoptosis detectionBacteroidesIntestinal microorganisms
The present invention provides a method capable of detecting a cancer and / or a carcinogenic risk, and a reagent for the detection thereof. The present invention also provides a method for screening for a pharmaceutical drug for reducing a carcinogenic risk and a pharmaceutical composition. Since cancer development closely correlates with alteration in gut microbiota, cancer development and / or a risk of cancer development are detected by detecting alteration in gut microbiota and a secondary bile acid produced by an intestinal bacterium. The present invention further provides a method for screening for a pharmaceutical drug with a gut microbiota as an index, and a pharmaceutical composition.
Owner:JAPANESE FOUND FOR CANCER RES
Application of bacteria in preparation of synergist of immune checkpoint inhibitor
ActiveCN114159475AImprove efficacyProlong survival timeBacteriaBacteria material medical ingredientsImmune protectionOverall survival
The invention discloses application of bacteria in preparation of a synergist of an immune checkpoint inhibitor. According to the present invention, the human endogenous intestinal bacterium single bacterium oral preparation is combined with the immune checkpoint inhibitor, and the anti-tumor immune protection reaction is generated through the endogenous intestinal bacterium stimulation, such that the drug effect of the immune checkpoint inhibitor on a plurality of tumor species is significantly enhanced, the safety is good, the overall survival time of cancer patients is prolonged, and the treatment effect is good. The response rate of cancer immunotherapy crowds is improved, and cancer immunotherapy benefiting tumor patient crowds are expanded.
Owner:SUN YAT SEN UNIV CANCER CENT
Dragonfly intestinal bacterium aspergillus terreus QT122 and metabolite and application thereof
The invention discloses aspergillus terreus QT122 which is Aspergillus terreus QT122, and its preservation number is CCTCC M 2015240. The invention also discloses preparation methods of an aspergillus terreus QT122 fermentation broth, an aspergillus terreus QT122 fermentation broth crude extract and an aspergillus terreus QT122 metabolite. The invention also discloses an application of aspergillus terreus QT122. The aspergillus terreus QT122 fermentation broth, the aspergillus terreus QT122 fermentation broth crude extract and the aspergillus terreus QT122 metabolite all can be used for inhibiting radicle growth of amaranthus retroflexus or barnyard grass. The aspergillus terreus QT122 fermentation broth, the aspergillus terreus QT122 fermentation broth crude extract and the aspergillus terreus QT122 metabolite can be used in the preparation of a biopesticide with an inhibitory activity to radicle growth of amaranthus retroflexus and barnyard grass.
Owner:ZHEJIANG NORMAL UNIVERSITY
Anti-bacterial composition against Th1 cell-inducing bacteria
ActiveCN110891583APrevent proliferationInhibitory activityAntibacterial agentsBacteriaBacterial compositionMicrobiology
Owner:KEIO UNIV
Composition for induced bowel movement and diet and preparation method thereof
PendingCN112040792ATo promote metabolismRaise the ratioOrganic active ingredientsAlgae medical ingredientsBiotechnologyGARLIC POWDER
Owner:RG生物有限公司
Bacillus Velez d2406 isolated from the intestinal tract of soldier flies and its application
ActiveCN112795501BImprove conversion rateIncrease reduction rateAntibacterial agentsBiocideBiotechnologyPyrazine
The invention belongs to the field of biology, and specifically discloses Bacillus Velez D2406 isolated from the intestinal tract of soldier flies and its application. The preservation number of the Bacillus Velez is CCTCC NO: M2020874. fly growth, and can stably inhibit Staphylococcus aureus in vitro and in soldier fly larvae. The intestinal bacterium of the invention can increase the conversion rate of larvae, increase the reduction rate of materials, increase the weight gain rate of larvae, and stably inhibit Staphylococcus aureus in the isolated condition and in soldier fly larvae. The volatile compound 2,5-dimethylpyrazine produced by the bacteria has a significant inhibitory effect on zoonotic pathogenic bacteria. Inoculation of the intestinal bacteria into the Soldier Fly transformation system not only improved the transformation efficiency of Soldier Fly larvae, but also reduced the abundance of Staphylococcus aureus in the transformation material, and it is expected to reduce the incidence of bacteria brought about by the use of chemical drugs. environmental pollution.
Owner:HUAZHONG AGRI UNIV
Disease-oriented nutrient intervention method and system, equipment and storage medium
ActiveCN113628714AEffectively determine the effect of an interventionOvercome physical differencesDrug and medicationsNutrition controlBiotechnologyMicrobiology
The invention relates to a disease-oriented nutrient intervention method and system, equipment and a storage medium, and the method comprises the steps: building a query database, wherein an incidence relation of the diseases, intestinal bacteria and nutrients is recorded in the query database; inputting a target disease into the query database, obtaining each pathogenic intestinal bacterium of the target disease and taking the pathogenic intestinal bacterium as a target bacterium, and obtaining a target nutrient commonly associated with each target bacterium; and determining the intervention effect of the target nutrient on the target disease according to the action effect of the target nutrient on each target bacterium and the action effect of each target bacterium on the target disease. According to the method and system, the intervention effect of the target nutrient on the target disease can be rapidly and effectively determined, different human body constitutions are overcome, and therefore a nutrient intervention scheme is provided for chronic diseases related to intestinal bacteria.
Owner:MEI YI TIAN BIOLOGICAL MEDICINE WUHAN CO LTD
Primer pairs and kits for detecting butyrate synthesis genes
ActiveCN109234397BImprove predictabilityOvercoming detection deficienciesMicrobiological testing/measurementDNA/RNA fragmentationDiseaseEnzyme synthesis
Owner:CHINA PHARM UNIV
Oral composition containing difructose anhydride
InactiveCN101056644AImprove the production effectIncrease concentrationOrganic active ingredientsDigestive systemFructoseMicrobiology
The present invention provides an oral composition for potentiating the production of equol by an intestinal bacterium which contains, as the active ingredient, difructose anhydride for activating the equol productivity of the intestinal bacterium.
Owner:FUAN KERU
Intestinal flora marker for predicting curative effect of immunotherapy and application of intestinal flora marker
PendingCN114085916AAddressing the Few Biomarkers AvailableUnsatisfactory solutionMicrobiological testing/measurementDisease diagnosisMelanomaClinical efficacy
The invention discloses an intestinal flora marker for predicting the curative effect of immunotherapy and application of the intestinal flora marker. The inventor screens out DNA detection targets with expression differences in patients with different clinical effects from 55 intestinal bacterium DNA detection targets, and can solve the problems that few biomarkers can be available for melanoma immunotherapy patients and the effect is not ideal. The relationship between the intestinal flora characteristics and the PD-1 / PD-L1 blocking treatment may have generality in different types of tumors; the research results of the project have the possibility of being applied to tumors except melanoma, such as sarcoma, kidney cancer, lung cancer, stomach cancer or colorectal cancer, and benefiting patients through data supplementation and reanalysis.
Owner:SUN YAT SEN UNIV CANCER CENT
Enterobacter 638 and its application method
The present invention relates to a novel species of Enterobacter, Enterobacter sp. 638, and to increased plant growth, e.g. Use of methods of growing, increasing plant biomass, increasing plant fruit and / or seed productivity, increasing plant disease tolerance and / or resistance and increasing plant drought tolerance and / or drought resistance. The method includes applying to the plant an effective amount of a composition comprising an isolated culture of Enterobacter 638.
Owner:BROOKHAVEN SCI ASSOCS
Judgment marker for cognitive impairment of Parkinson's disease and application thereof
PendingCN114085899AComprehensive understanding of pathological mechanismsUnderstanding pathological mechanismsComponent separationMicrobiological testing/measurementGut floraPsychiatry
The invention discloses a judgment marker for cognitive impairment of Parkinson's disease and application thereof The inventor of the invention finds that the relative abundance of the intestinal bacteria in the excrement of a PD patient is significantly related to PD-MCI, and the concentrations of isobutyric acid and isovaleric acid are related to the overall cognitive level. The composition characteristics of intestinal flora and metabolites of a PD-CI patient are researched from the metagenome level and the metabolome level, and the pathological mechanism of the PD-CI can be more comprehensively understood; and early intervention is also facilitated to slow down or treat the development of PD-CI.
Owner:GUANGDONG GENERAL HOSPITAL
Anti-bacterial composition against th1 cell-inducing bacteria
ActiveUS20200171099A1Suppress activationSuppress cell proliferationAntibacterial agentsBacteriaBacterial compositionMedicine
With the aim of proving an antibacterial composition against oral bacteria and the like capable of inducing Th1 cell proliferation or activation in an intestinal tract, the present inventors have found out that bacteria that suppress colonization and the like of the oral bacteria and the like in the intestinal tract are present in an intestinal microbiota. Moreover, the present inventors have succeeded in isolating intestinal bacteria that suppress intestinal colonization and the like of oral bacteria and the like.
Owner:KEIO UNIV
Method for producing 1,3-propylene glycol through ferment in high cell density by using bacteria in intestinal tract
InactiveCN1329518CIncrease production intensityIncrease concentrationMicroorganism based processesFermentationPhosphateNutrient solution
A method of preparing 1, 3- propylene glycol by high cell density intestinal uses the method of fermentation. Its process: seed culturing the intestinal bacterium is activated and then inoculated in the nutrient solution with no bacterium seed; the raises process of fermentation nutrient solution: when this solution is disinfected and cool, we inoculate the seed solution with the volume rate 3-15% into a tank of fermentation solution; the fast grow period of separated fermentation solution: the density of carbon retains 0.1-30g / L; high cell density fermentation period: the density of the bacterium seed reaches OD6502.0-5.0; it adapts the way of limited accommodate of alimentation and air; when the product has been synthesized, we add nitrogen, phosphate, inorganic ion, trace element,VB12 or their mixture of one or several components, and simultaneously add flowing glycerin; when there is acid, the fermentation process finishes.
Owner:SOUTHEAST UNIV
Gestational diabetes biomarkers of intestinal bacteria in early pregnancy as well as screening and application of gestational diabetes biomarkers
InactiveCN113174444AImprove predictive performanceResearch stability and accuracyHealth-index calculationMicrobiological testing/measurementPregnancyBiomarker (medicine)
The invention discloses gestational diabetes biomarkers of intestinal bacteria in early pregnancy as well as screening and application of the gestational diabetes biomarkers, and belongs to the field of intestinal flora and human health research. 27 intestinal bacterium biomarkers and 4 intestinal bacterium calculation indexes are included. The sample DNA is subjected to 16S rDNA amplicon library building and sequencing, and the structure and function information of intestinal flora and the relevance with gestational diabetes are analyzed. Regression model inspection shows that the screened 6 types of intestinal bacteria significantly improve the prediction efficiency of a gestational diabetes basic prediction model. The relative abundance of the staphylococcus and the 4 types of short-chain fatty acid producing bacteria is higher than that of a log converted value in a case group, and is positively correlated with fasting blood-glucose, 1h blood-glucose level and 2h blood-glucose level in the middle pregnancy period. The biomarkers provided by the invention can be used as a detection target for preparing a kit for predicting the onset risk of gestational diabetes at the early pregnancy stage, or can be used as a target for preparing a medicine for treating and / or preventing gestational diabetes.
Owner:HUAZHONG UNIV OF SCI & TECH
Method for screening food ingredients and food compositions
ActiveUS20160002699A1Promote the balance of intestinal floraReduce cancer riskMilk preparationMicrobiological testing/measurementBacteroidesMetabolite
The present invention provides a method for screening for a food ingredient or a food composition that reduces a cancer risk and inhibits cancer development. A substance that reduces a cancer risk is screened by administering a candidate substance and analyzing alteration in gut microbiota or a metabolite produced by an intestinal bacterium. Also, candidate substances are screened by adding each candidate substance to a bacterial culture system and analyzing its effect on a bacterium involved in cancer development.
Owner:JAPANESE FOUND FOR CANCER RES
Method for screening food ingredients and food compositions
ActiveUS9856507B2Improve balanceReduce cancer riskMicrobiological testing/measurementBiological material analysisMetaboliteAdditive ingredient
The present invention provides a method for screening for a food ingredient or a food composition that reduces a cancer risk and inhibits cancer development. A substance that reduces a cancer risk is screened by administering a candidate substance and analyzing alteration in gut microbiota or a metabolite produced by an intestinal bacterium. Also, candidate substances are screened by adding each candidate substance to a bacterial culture system and analyzing its effect on a bacterium involved in cancer development.
Owner:JAPANESE FOUND FOR CANCER RES
Method for examination of carcinogenic risk
ActiveUS9670550B2Increased riskImprove the situationCompound screeningApoptosis detectionIntestinal microorganismsPharmaceutical drug
The present invention provides a method capable of detecting a cancer and / or a carcinogenic risk, and a reagent for the detection thereof. The present invention also provides a method for screening for a pharmaceutical drug for reducing a carcinogenic risk and a pharmaceutical composition. Since cancer development closely correlates with alteration in gut microbiota, cancer development and / or a risk of cancer development are detected by detecting alteration in gut microbiota and a secondary bile acid produced by an intestinal bacterium. The present invention further provides a method for screening for a pharmaceutical drug with a gut microbiota as an index, and a pharmaceutical composition.
Owner:JAPANESE FOUND FOR CANCER RES